Stage T1c prostate cancer: defining the appropriate staging evaluation and the role for pelvic lymphadenectomy
A good staging system should be able to accurately reflect the natural history of a malignant disease, to express the extent of the disease at the time of diagnosis, and stratify patients in prognostically distinctive groups. The staging system for prostate cancer, as it is today, fails to fulfill t...
Gespeichert in:
| Veröffentlicht in: | World journal of urology 1997-11, Vol.15 (6), p.346-358 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 358 |
|---|---|
| container_issue | 6 |
| container_start_page | 346 |
| container_title | World journal of urology |
| container_volume | 15 |
| creator | Beduschi, M C Beduschi, R Oesterling, J E |
| description | A good staging system should be able to accurately reflect the natural history of a malignant disease, to express the extent of the disease at the time of diagnosis, and stratify patients in prognostically distinctive groups. The staging system for prostate cancer, as it is today, fails to fulfill these requirements. Approximately one third of the patients who undergo surgery for complete excision of prostate cancer in fact do not have a localize disease. The incidence of tumor at the inked margin may reach 30% for T1 stage and up to 60% for clinical T2b prostate cancer according to comparison with pathologic examination of resected specimen. Several concepts have been recently proposed as a means of improving the accuracy of the available staging system. In this paper, we review current aspects of clinical and pathological staging of prostate cancer, and the importance of these new concepts on the early stages of prostate cancer. |
| doi_str_mv | 10.1007/BF01300182 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79516418</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2716508281</sourcerecordid><originalsourceid>FETCH-LOGICAL-c237t-15faacdf5536738e24052a6cbf8e79780014002584c183d58292c9b10e65d6603</originalsourceid><addsrcrecordid>eNpd0c9LwzAUB_Agis7pxbsQEDwI1fxO6k2HU2HgwXkuWfq6dbRpbdPB_nszHQqeAsknj_e-D6ELSm4pIfrucUooJ4QadoBGVHCeGM3UIRoRzUQiUsNP0GnfryPRishjdJwKrpgRI-Tfg10CnlOH267pgw2AnfUOunucQ1H60i9xWAG2bXxvu3IHIlvu7mFjq8GGsvHY-vybdU0FuGg63EK1KR2utnW7sjl4cKGpt2foqLBVD-f7c4w-pk_zyUsye3t-nTzMEse4DgmVhbUuL6TkSnMDTBDJrHKLwoBOtYmDCEKYNMJRw3NpWMpcuqAElMyVInyMrn_qxqY_B-hDVpe9g6qyHpqhz3QqqRLx7xhd_YPrZuh87C2jhGkqtJEqqpsf5WJGfQdFFpOobbeNKNutIPtbQcSX-5LDoob8l-4z51-b_3_S</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1027147856</pqid></control><display><type>article</type><title>Stage T1c prostate cancer: defining the appropriate staging evaluation and the role for pelvic lymphadenectomy</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Beduschi, M C ; Beduschi, R ; Oesterling, J E</creator><creatorcontrib>Beduschi, M C ; Beduschi, R ; Oesterling, J E</creatorcontrib><description>A good staging system should be able to accurately reflect the natural history of a malignant disease, to express the extent of the disease at the time of diagnosis, and stratify patients in prognostically distinctive groups. The staging system for prostate cancer, as it is today, fails to fulfill these requirements. Approximately one third of the patients who undergo surgery for complete excision of prostate cancer in fact do not have a localize disease. The incidence of tumor at the inked margin may reach 30% for T1 stage and up to 60% for clinical T2b prostate cancer according to comparison with pathologic examination of resected specimen. Several concepts have been recently proposed as a means of improving the accuracy of the available staging system. In this paper, we review current aspects of clinical and pathological staging of prostate cancer, and the importance of these new concepts on the early stages of prostate cancer.</description><identifier>ISSN: 0724-4983</identifier><identifier>EISSN: 1433-8726</identifier><identifier>DOI: 10.1007/BF01300182</identifier><identifier>PMID: 9436284</identifier><language>eng</language><publisher>Germany: Springer Nature B.V</publisher><subject>Humans ; Lymph Node Excision ; Male ; Medical research ; Neoplasm Staging ; Pelvis - surgery ; Prostate cancer ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - surgery ; Time Factors</subject><ispartof>World journal of urology, 1997-11, Vol.15 (6), p.346-358</ispartof><rights>Springer-Verlag 1997</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c237t-15faacdf5536738e24052a6cbf8e79780014002584c183d58292c9b10e65d6603</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9436284$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Beduschi, M C</creatorcontrib><creatorcontrib>Beduschi, R</creatorcontrib><creatorcontrib>Oesterling, J E</creatorcontrib><title>Stage T1c prostate cancer: defining the appropriate staging evaluation and the role for pelvic lymphadenectomy</title><title>World journal of urology</title><addtitle>World J Urol</addtitle><description>A good staging system should be able to accurately reflect the natural history of a malignant disease, to express the extent of the disease at the time of diagnosis, and stratify patients in prognostically distinctive groups. The staging system for prostate cancer, as it is today, fails to fulfill these requirements. Approximately one third of the patients who undergo surgery for complete excision of prostate cancer in fact do not have a localize disease. The incidence of tumor at the inked margin may reach 30% for T1 stage and up to 60% for clinical T2b prostate cancer according to comparison with pathologic examination of resected specimen. Several concepts have been recently proposed as a means of improving the accuracy of the available staging system. In this paper, we review current aspects of clinical and pathological staging of prostate cancer, and the importance of these new concepts on the early stages of prostate cancer.</description><subject>Humans</subject><subject>Lymph Node Excision</subject><subject>Male</subject><subject>Medical research</subject><subject>Neoplasm Staging</subject><subject>Pelvis - surgery</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - surgery</subject><subject>Time Factors</subject><issn>0724-4983</issn><issn>1433-8726</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpd0c9LwzAUB_Agis7pxbsQEDwI1fxO6k2HU2HgwXkuWfq6dbRpbdPB_nszHQqeAsknj_e-D6ELSm4pIfrucUooJ4QadoBGVHCeGM3UIRoRzUQiUsNP0GnfryPRishjdJwKrpgRI-Tfg10CnlOH267pgw2AnfUOunucQ1H60i9xWAG2bXxvu3IHIlvu7mFjq8GGsvHY-vybdU0FuGg63EK1KR2utnW7sjl4cKGpt2foqLBVD-f7c4w-pk_zyUsye3t-nTzMEse4DgmVhbUuL6TkSnMDTBDJrHKLwoBOtYmDCEKYNMJRw3NpWMpcuqAElMyVInyMrn_qxqY_B-hDVpe9g6qyHpqhz3QqqRLx7xhd_YPrZuh87C2jhGkqtJEqqpsf5WJGfQdFFpOobbeNKNutIPtbQcSX-5LDoob8l-4z51-b_3_S</recordid><startdate>19971101</startdate><enddate>19971101</enddate><creator>Beduschi, M C</creator><creator>Beduschi, R</creator><creator>Oesterling, J E</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>19971101</creationdate><title>Stage T1c prostate cancer: defining the appropriate staging evaluation and the role for pelvic lymphadenectomy</title><author>Beduschi, M C ; Beduschi, R ; Oesterling, J E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c237t-15faacdf5536738e24052a6cbf8e79780014002584c183d58292c9b10e65d6603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Humans</topic><topic>Lymph Node Excision</topic><topic>Male</topic><topic>Medical research</topic><topic>Neoplasm Staging</topic><topic>Pelvis - surgery</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - surgery</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Beduschi, M C</creatorcontrib><creatorcontrib>Beduschi, R</creatorcontrib><creatorcontrib>Oesterling, J E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>World journal of urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Beduschi, M C</au><au>Beduschi, R</au><au>Oesterling, J E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stage T1c prostate cancer: defining the appropriate staging evaluation and the role for pelvic lymphadenectomy</atitle><jtitle>World journal of urology</jtitle><addtitle>World J Urol</addtitle><date>1997-11-01</date><risdate>1997</risdate><volume>15</volume><issue>6</issue><spage>346</spage><epage>358</epage><pages>346-358</pages><issn>0724-4983</issn><eissn>1433-8726</eissn><abstract>A good staging system should be able to accurately reflect the natural history of a malignant disease, to express the extent of the disease at the time of diagnosis, and stratify patients in prognostically distinctive groups. The staging system for prostate cancer, as it is today, fails to fulfill these requirements. Approximately one third of the patients who undergo surgery for complete excision of prostate cancer in fact do not have a localize disease. The incidence of tumor at the inked margin may reach 30% for T1 stage and up to 60% for clinical T2b prostate cancer according to comparison with pathologic examination of resected specimen. Several concepts have been recently proposed as a means of improving the accuracy of the available staging system. In this paper, we review current aspects of clinical and pathological staging of prostate cancer, and the importance of these new concepts on the early stages of prostate cancer.</abstract><cop>Germany</cop><pub>Springer Nature B.V</pub><pmid>9436284</pmid><doi>10.1007/BF01300182</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0724-4983 |
| ispartof | World journal of urology, 1997-11, Vol.15 (6), p.346-358 |
| issn | 0724-4983 1433-8726 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79516418 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Humans Lymph Node Excision Male Medical research Neoplasm Staging Pelvis - surgery Prostate cancer Prostatic Neoplasms - pathology Prostatic Neoplasms - surgery Time Factors |
| title | Stage T1c prostate cancer: defining the appropriate staging evaluation and the role for pelvic lymphadenectomy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T23%3A07%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stage%20T1c%20prostate%20cancer:%20defining%20the%20appropriate%20staging%20evaluation%20and%20the%20role%20for%20pelvic%20lymphadenectomy&rft.jtitle=World%20journal%20of%20urology&rft.au=Beduschi,%20M%20C&rft.date=1997-11-01&rft.volume=15&rft.issue=6&rft.spage=346&rft.epage=358&rft.pages=346-358&rft.issn=0724-4983&rft.eissn=1433-8726&rft_id=info:doi/10.1007/BF01300182&rft_dat=%3Cproquest_cross%3E2716508281%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1027147856&rft_id=info:pmid/9436284&rfr_iscdi=true |